Abbott Laboratories — Oct 15, 2025 release

• Year-to-date sales increased 6.1 percent on a reported basis, 6.4 percent on an organic basis, or 7.7 percent when excluding COVID-19 testing-related sales 2 . • Abbott reaffirms previously provided full-year 2025 organic sales growth guidance. • Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint. • In July, Abbott announced it received regulatory approval in Japan for TriClip ® , a first of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation, or a leaky tricuspid heart valve. • In August, Abbott announced it received CE Mark for an expanded indication for the company's Navitor ® transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. • In August, at the European Society of Cardiology (ESC) Congress, new treatment guidelines were issued that provide additional support for the use of MitraClip ® and TriClip in treating valvular heart disease. These new guidelines were backed by evidence from multiple clinical studies. "Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders."   Page 1 of 20 THIRD-QUARTER BUSINESS OVERVIEW Ma